Trial
NCT05282121
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Liver Diseases
Intervention
Avenciguat
Why stopped
Company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-04